secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001104659-24-126758
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel reports initial Phase 1b data for R289 in LR-MDS; 40% response rate in evaluable TD patients at ≥500 mg QD
--------------------------------------------------------------------------------

- 22 LR-MDS patients enrolled; median age 76, median 3 prior therapies; 73% high transfusion burden.
- R289 well tolerated; most common AEs diarrhea/fatigue (27%), chills/nausea/pruritus (23%), all Grade 1/2.
- Among evaluable TD patients at doses ≥500 mg QD, 40% (4/10) achieved RBC-TI/HI-E; 3 achieved RBC-TI ≥8 weeks.
- Two HTB patients achieved RBC-TI >24 weeks; median RBC-TI duration 29 weeks (range 12.7-51.9 weeks).
- FDA granted Fast Track designation for R289 in previously-treated transfusion-dependent LR-MDS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924126758/0001104659-24-126758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924126758/tm2430504d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-126758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer